PhoenixBio is delighted to be attending AASLD in person at the Walter E. Washington Convention Center in Washington, DC on November 4th - 8th, 2022. We'll be exhibiting our products & services at booth #714. Meet with our team to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s therapies.
While you're there, be sure to check posters featuring our technology & models:
- Abstract 22: “Shortening HBV Treatment and Preventing HBV Relapse by Adding an Anti-HBV Expressing AAV-Vector to Entecavir Therapy in HBV Infected cDNA-uPA/SCID Chimeric Mice”
- Abstract 1129: “Role of Hepatic Antiviral Innate Immunity In Regulating The Dynamics Of HBV-HDV Infection And Determining The Efficacy Of IFN-Based Antiviral Therapy”
- Abstract 1142: “Accumulation of Hepatitis B Surface Antigen Provokes Er Stress Mediated Cell Death in Basal Core Promoter and Precore Mutated Hepatitis B Virus Infection”
- Abstract 1146: “A Novel, Small Anti-HBV Compound Reduces HBsAg And HBV DNA by Destabilizing HBV RNA”
- Abstract 1147: “HBV Upregulates TRAIL-R3 Expression in Hepatocytes for Escaping Both Cell Apoptosis and Suppression of Their Replication by TRAIL”
- Abstract 1192: “Investigation of Infectivity of Serum-Derived HBV from Patients and Human Hepatocyte Chimeric Mouse to HepG2/NTCP Cells”
- Abstract 2532: “TLC-2716, a Potent, Liver-Targeted, Inverse Agonist of the Liver X Receptor (LXR), Demonstrates Profound Reductions in Hepatic and Plasma Lipids in Dysmetabolic Rodent Models”
- Abstract 2547: “Transcriptomic and Metabolomic Analysis of Growth Hormone Response in a Fatty Liver Model Using Human Hepatocyte Chimeric Mice”
- Abstract 4112: “Establishment of A Stepwise Human Hepatocyte In Vitro Culture System for Long-Term Cell Fate and Functional Maintenance”
